Pfizer and Valneva Complete Recruitment for Phase 3 VALOR Trial for Lyme Disease Vaccine Candidate, VLA15GlobeNewsWire • 12/04/23
Pfizer Shares Drop as It Ends Study of Weight-Loss Pill Due to Patient Side EffectsInvestopedia • 12/01/23
Pfizer Halts Development Of Twice-Daily Weight-Loss Drug; PFE Stock SlidesInvestors Business Daily • 12/01/23
Pfizer Pulls Experimental Twice-Daily Weight Loss Drug—Shares Slide 6% To Multiyear LowForbes • 12/01/23
Pfizer's stock falls 4% after saying it will not move to Phase 3 trial of weight-loss drug as twice-daily formationMarket Watch • 12/01/23
Pfizer Announces Topline Phase 2b Results of Oral GLP-1R Agonist, Danuglipron, in Adults with ObesityBusiness Wire • 12/01/23
Covid vaccine rates in the U.S. are slumping — and it will be a challenge to boost themCNBC • 11/30/23